Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review

Garduno, Javier; Bhosle, Monali; Balkrishnan, Rajesh; Feldman, Steven R.

doi:10.1080/09546630701271807

Cited by 37 publications

(25 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This 10-item questionnaire is the internationally most commonly used measure of HRQoL in psoriasis [23]. All items of the DLQI relate to impairments due to skin condition in the preceding week including the extent of itching, pain and burning sensations, shame due to the skin, and the influence of the symptoms on daily activities, work, leisure, relationships and social life.…”

Section: Methodsmentioning

confidence: 99%

Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis

Blome¹,

Simianer²,

Purwins³

et al. 2010

Dermatology

View full text Add to dashboard Cite

Background: The literature on predictors of health-related quality of life in psoriasis is inconsistent. Objective: To assess potential predictors of quality of life in psoriasis. Methods: In a cross-sectional study involving 130 dermatological practices and outpatient clinics, data of 1,210 patients with psoriasis were collected. Quality of life was evaluated using the Dermatology Life Quality Index. Medical history, clinical and sociodemographic characteristics, therapy and health care features were used as independent variables in a backward multiple regression analysis. Results: Twelve predictors were included in the model explaining 38% of variance in quality of life. The strongest predictor was daily treatment time (β = 0.30), followed by patient-defined treatment benefit (β = –0.18), disease severity (β = 0.19) and treatment satisfaction (β = –0.16). Conclusion: Treatment burden requires special attention when quality of life in psoriasis is to be improved. Since the larger part of variance is left unexplained, further factors predicting quality of life have yet to be detected.

show abstract

Section: Methodsmentioning

confidence: 99%

Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis

Blome¹,

Simianer²,

Purwins³

et al. 2010

Dermatology

View full text Add to dashboard Cite

show abstract

“…Biological treatment was indicated in patients where at least two standard systemic treatments proved ineffective or in patients where conventional treatment was contraindicated. Report -decrease in % Standard PASI (Psoriasis Area Severity Index) and BSA (Body Surface Area) indexes were used in weeks 0, 12, 24 for evaluation of clinical findings [15][16][17] . The data were statistically analysed using SPSS software version 15 (SPSS Inc., Chicago, USA).…”

Section: Methodsmentioning

confidence: 99%

Experience with the systemic treatment of severe forms of psoriasis

Tichý¹,

Zapletalová²

2012

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Introduction. Severe forms of psoriasis are indicated for systemic treatment with conventional and biological preparations . The former includes methotrexate, cyclosporin, acitretin and narrow-band ultraviolet B phototherapy but toxicity may limit the dose and duration of treatment. Currently used less toxic biological preparations include inhibitors of TNF-alpha (etanercept, adalimumab, infliximab) and the monoclonal antibody against IL 12/23 ustekinumab. We present our own more than five-year experience with the systemic treatment of severe forms of psoriasis using these preparations. Methods. A total of 66 patients treated with systemic therapy (except for phototherapy) were divided into groups based on treatment. Therapeutic doses were administered according to the recommendations of the manufacturer and dermatological societies. Standard PASI and BSA indexes were used to evaluate clinical condition at weeks 0, 12 and 24. Results. Differences in PASI score reduction and BSA index between patient groups treated with different preparations were statistically significant at monitored intervals. At week 12, PASI score was reduced by 75% or more in a significantly greater number of patients treated with infliximab + methotrexate than those treated with acitretin. At week 24, identical comparison showed a significantly greater number of patients treated with etanercept or adalimumab than those receiving methotrexate. For BSA index reduction by 50% or more, no statistically significant differences were found between patient groups during the follow-up period. Conclusion. Systemic therapy provides a significant benefit to patients with severe psoriasis. Biological preparations are more effective than conventional medications which are often limited by severe side-effects and generally less tolerated than biological treatments.

show abstract

“…There are a number of measures to assess psoriasis [11,12]. Whereas the clinical measure psoriasis area and severity index (PASI) and the dermatology-specific HRQOL measure dermatology quality of life index (DLQI) are widely used and valid measures in psoriasis [11,12,13,14,15,16,17]; the generic preference-based EQ-5D questionnaire is a good complement [18], essential in cost-effectiveness analyses [19].…”

Section: Introductionmentioning

confidence: 99%

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

et al. 2012

View full text Add to dashboard Cite

Background: Although clinical studies have shown efficacy of biological agents in moderate to severe psoriasis, observational studies of real-world effectiveness are rare. Objective: To analyse the psoriasis area and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological agents. Methods: Longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Pso-riasis, PsoReg. Outcomes of biological-naïve patients who switched to a biological agent (n = 267) were analysed before switch and at the first follow-up. Results: Patients significantly improved in EQ-5D, DLQI and PASI (p < 0.001). Patients with DLQI ≥10 and/or PASI ≥10 had the greatest benefits from biological agents in terms of EQ-5D. Conclusions: Patients with moderate to severe psoriasis benefit from biological agents in clinical practice; the patients with the highest benefits were those with high pretreatment PASI and DLQI scores.

show abstract

Measures used in specifying psoriasis lesion(s), global disease and quality of life: A systematic review

Abstract: Various measures are being utilized for the same purpose of generalizing disease/lesion severity and determining 'quality of life'.

Cited by 37 publications

References 4 publications

Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis

Time Needed for Treatment Is the Major Predictor of Quality of Life in Psoriasis

Experience with the systemic treatment of severe forms of psoriasis

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Contact Info

Product

Resources

About